Merck Serono S. A.

Merck Patent Gmbh

Applied Research Systems Ars Holding N.v.

Columbia University

Amgen Inc.

Laboratoires Serono S.a.

Xuliang Jiang

Andreas Goutopoulos

Meinolf Thiemann

Matthias Schwarz

Sean D McKenna

Stephen Arkinstall

Kerstin Otte

Holger Deppe

Ulrich Grädler

Marianne Donnelly

Santosh Shripad Kulkarni

Achim Feurer

Henry Yu

Renate Sekul

Ulrich Abel

William Harold Brondyk

Ngan Nguyen

Robert K Campbell

Sharad Magar

Rene Lynn Schweickhardt

Peter Blume-Jensen

Marco Muda

Antonio Arulanandam

Roustem Nabioullin

John Yingsheng Zhang

Theresa L Johnson

Srinivasa R Karra

Thomas E Richardson

Thomas Rueckle

Dennis Church

Benny C Askew

Catherine Jorand-LeBrun

Pascale Gaillard

Mark Tepper

Christie Ann Kelton

Ulrich Graedler

Keith E Langley

Wayne A Hendrickson

Rashid Syed

Giampiero De Luca

Lizbeth Celeste De Selm

Chaomei He

Tania Grippi Vallotton

Yueh-Rong Ann Hsu

Louise M Garone

Meijia Yang

Jr Benny C Askew

Stephen J Arkinstall

Robert Campbell

The present invention relates to pyrazole compounds, and pharmaceutically acceptable compositions thereof, useful as positive allosteric modulators of follicle stimulating hormone receptor (FSHR).

Pyrazole compounds as modulators of FSHR and uses thereof

The present invention relates to imidazole compounds, and pharmaceutically acceptable compositions thereof, useful as positive allosteric modulators of follicle stimulating hormone receptor (FSHR).

Imidazole compounds as modulators of FSHR and uses thereof

The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cyclophilins, and for the treatment of cyclophilin-related disorders.

Compounds for the inhibition of cyclophilins and uses thereof

The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.

3-arylamino pyridine derivatives

Macrocyclic derivative compounds that inhibit protein kinase enzymes are disclosed along with pharmaceutical compositions comprising these compounds and methods for synthesizing the same. Such compounds have utility in the treatment of proliferative diseases resulting from unregulated and/or disturbed kinase activity such as cancers, psoriasis, viral and bacterial infections, inflammatory and autoimmune diseases.

Macrocyclics pyrimidines as aurora kinase inhibitors

The invention provides novel, substituted 3-arylamino pyridine compounds (I) pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds. 

FSH mutant with increased glycosylation and longer half-life is described. The use of this FSH mutant for inducing folliculogenesis in human patients is also described.

FSH glycosylation variant D3N

The present invention is related to azolidinedione-vinyl fused-benzene derivatives of formula (I) for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, graft rejection or lung injuries. Formula (I), wherein A, X, Y, Z, R, Rand n are as described in the description. 

Azolidinone-vinyl fused-benzene derivatives

This disclosure relates to hybrid antigen binding molecules including at least two polypeptide chains, with at least one polypeptide chain comprises an antigen binding moiety linked to an amino acid sequence of a subunit of a heterodimeric proteinaceous hormone. Also disclosed are methods of making and using such hybrid antigen binding molecules for diagnosis and/or therapy.

Compositions and methods of producing hybrid antigen binding molecules and uses thereof

FSH mutants with increased glycosylation and longer half-lives are described. The use of FSH mutants for inducing folliculogenesis in human patients is also described.

FSH mutants

A novel FSH mutant with increased glycosylation and longer half-lifes for use in inducing folliculogenesis in human patients is described. The FSH mutant permits the use of lower cumulative doses of FSH to achieve the same or better clinical result.

FSH beta mutants that are glycosilated at residues N55 and T57

The invention provides substituted pyrazolidinone compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing various cancers, inflammation, septic shock, preterm labor, infertility, pain, and ischemia, and other diseases and disorders associated with MEK-1 and/or ERK-2 activation.

Azole derivatives and pharmaceutical compositions containing them

Growing community of inventors

Braintree, MA, United States of America

Xuliang Jiang